Detalles de la búsqueda
1.
Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer.
BMC Cancer
; 23(1): 606, 2023 Jun 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37391697
2.
Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study.
Breast Cancer Res
; 24(1): 90, 2022 12 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36527133
3.
Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92-Gene Assay.
Oncologist
; 25(11): e1807-e1811, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32893931
4.
Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score.
Breast Cancer Res Treat
; 173(2): 375-383, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30350269
5.
Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study.
Breast Cancer Res
; 18(1): 1, 2016 Jan 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-26728744
6.
Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14.
Breast Cancer Res Treat
; 157(1): 101-8, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27116182
7.
Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma.
BMC Cancer
; 16: 668, 2016 08 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-27549176
8.
Development and validation of a 32-gene prognostic index for prostate cancer progression.
Proc Natl Acad Sci U S A
; 110(15): 6121-6, 2013 Apr 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-23533275
9.
A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumors.
Mod Pathol
; 27(1): 44-54, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23846576
10.
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Lancet Oncol
; 14(11): 1067-1076, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24035531
11.
Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial.
Clin Cancer Res
; 30(9): 1984-1991, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38376912
12.
Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor-Positive Postmenopausal Breast Cancer Patients in the TEAM Trial.
Clin Cancer Res
; 30(8): 1509-1517, 2024 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38345755
13.
Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes.
Cancer Cell
; 42(2): 225-237.e5, 2024 02 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38278149
14.
Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study.
Clin Cancer Res
; 28(9): 1871-1880, 2022 05 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35144966
15.
Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study.
J Clin Oncol
; 39(2): 126-135, 2021 01 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33108242
16.
Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma.
Clin Cancer Res
; 27(20): 5688-5696, 2021 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34376532
17.
Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy.
Clin Cancer Res
; 27(1): 311-319, 2021 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33109739
18.
Multi-Institutional, Prospective Clinical Utility Study Evaluating the Impact of the 92-Gene Assay (CancerTYPE ID) on Final Diagnosis and Treatment Planning in Patients With Metastatic Cancer With an Unknown or Unclear Diagnosis.
JCO Precis Oncol
; 2: 1-12, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35135112
19.
Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer.
NPJ Breast Cancer
; 3: 28, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28795152
20.
A Novel Breast Cancer Index for Prediction of Distant Recurrence in HR+ Early-Stage Breast Cancer with One to Three Positive Nodes.
Clin Cancer Res
; 23(23): 7217-7224, 2017 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28939745